Ceribell, Inc. earnings date
Want to see CBLL full AI Analyst Report?
Ceribell, Inc. (CBLL) Q3 2026 Earnings Report
CBLL Q3 2026 EPS Results
- Actual EPS
- -$0.55
- Consensus EPS
- -$0.51
- Beat/Miss
- Missed by -$0.04
- One Year Ago EPS
- -$0.37
CBLL Q3 2026 Revenue Results
- Actual Revenue
- $29.34M
- Expected Revenue
- $29.18M
- Beat/Miss
- Beat by +$162.00K
- YoY Revenue Growth
- +29.89%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- After Close
- Conference Call
- Tuesday, November 3, 2026
Ceribell, Inc.'s next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive overall. CeriBell delivered approximately 30% revenue growth, record account additions, double-digit utilization growth, higher gross margins, raised full-year revenue guidance, and encouraging results from its delirium monitoring pilot. The company also outlined multiple product and market expansion initiatives for 2027. Offsetting factors included a wider net loss and adjusted EBITDA loss, operating expenses growing faster than revenue, ongoing litigation exposure, early-stage contributions from newer products, and the expectation that broad delirium adoption will take time.
CeriBell expects full year 2026 revenue to range from $115 million to $117 million, up from prior guidance of $114 million to $117 million, representing annual growth of 29% to 31% over 2025; this range does not include material contributions from neonate, pediatric, or delirium products, which are expected to begin translating to revenue more meaningfully in 2027. Based on today's tariff policy and current inventory position, the company expects to maintain margins in the high 80% range going forward, expects interest expense to decrease materially going forward to less than $1 million annually, and remains committed to achieving cash flow breakeven with cash on hand. CeriBell expects many accounts to adopt its delirium monitoring solution quickly, but broad-scale conversion will occur over time, with a more granular perspective on anticipated revenue impact planned as part of 2027 financial guidance; VA commitments are expected to roll into the account base over the next 2 to 3 quarters or so, qEEG features will be released next year, and Omni will have a limited market release this quarter with the product expected to launch in 2027.
- Strong Quarterly Revenue GrowthQ3 2026 revenue was $29.3 million, an approximately 30% increase from $22.6 million in Q3 2025 and a 4% sequential increase. Growth was driven by same-store growth, increased adoption across new and existing accounts, more accounts, and deeper penetration within the installed base.
- Product and Subscription Revenue ExpansionProducts revenue was $22.2 million, up 31% from $17.0 million in the prior-year quarter. Subscription revenue was $7.1 million, up 28% from $5.6 million. Management said product revenue benefited from record utilization, while subscription revenue remains a durable long-term growth driver.
- Record Account Additions and Installed Base GrowthCeriBell added a record 35 hospitals in Q3, ending the quarter with 747 active accounts. Management also cited a robust pipeline of unlaunched accounts expected to support sustained growth in coming quarters.
- Record Utilization and Department ExpansionYear-over-year usage per account grew at a double-digit rate, the highest level since the IPO. Management attributed the continued execution to provider engagement, department expansion, and patient population protocolization. More departments were added year-to-date in 2026 than during all of 2025, with expansion into emergency departments accelerating.
- Strategic Account Management ProgressThe newly established strategic account management team is generating positive signs through top-down engagement with regional health systems. Although these opportunities have inherently longer sales cycles, larger deals are advancing through the sales funnel.
- VA and DoD Growth OpportunitiesCeriBell reported strong engagement with VA and DoD health systems and secured a commitment to further expand within the VA. The commitment is reasonably in line with last year’s size, with accounts expected to roll into the account base over the next 2 to 3 quarters.
- Neonate Product Pipeline DevelopmentInterest in the neonate product remains strong, with ongoing pipeline development and NICU activation within new and existing accounts.
- Positive Delirium Monitoring Pilot ResultsThe delirium monitoring pilot showed meaningful impact in optimizing patient care and validating the solution as a new revenue stream. Customers reported improved clinical decision-making and positive user experiences, and the solution enabled long-term monitoring for the first time in many cases.
- Demonstrated Clinical Utility in Sepsis CaseIn a patient with sepsis and altered neurological status, the system returned a seizure-negative and delirium-positive result. This prompted a multidisciplinary review that identified cefepime as a potential contributor to delirium, led to an antibiotic change, and enabled continuous monitoring. The patient’s delirium trend decreased, and by day 3 the patient was no longer delirium positive.
- Delirium Pilot Generated Commercial Usage ImpactEstablished customers that launched delirium monitoring showed a material increase in headband utilization. The usage impact was present before NTAP took effect on October 1, which management said indicated clinical utility was a primary driver. The earliest customers had at least 120 days of usage following launch, and more recently launched accounts showed an even larger usage impact.
- Low-Friction Delirium Commercial Launch ModelCeriBell is offering delirium monitoring as a software upgrade at no incremental increase to the subscription fee, while requiring customer program commitments such as training more than 80% of nurses and physicians, aligning on KPIs, and ensuring sufficient recorder capacity. The launch will use the existing sales organization and is intended to avoid lengthy sales and contracting processes.
- New FDA-Cleared Algorithm CapabilitiesCeriBell recently received FDA 510(k) clearance for quantitative EEG trending and Amplitude-Integrated EEG Analysis. The qEEG functionality includes alpha-delta ratio, relative alpha trending, and burst suppression monitoring, with cloud-based software updates planned for next year.
- Continued Algorithm and Clinical Program DevelopmentThe company continues to develop additional algorithms, and its LVO stroke clinical program is progressing. Management said these efforts are intended to increase clinical utility and support longer-term market expansion.
- Omni Platform IntroductionCeriBell unveiled Omni, its next-generation hardware platform designed to run all of its algorithms and support seizure, status epilepticus, delirium, and other brain-stress indicators. The platform adds video, multiple-day continuous monitoring, EKG compatibility, and a parasagittal add-on for full montage coverage when needed.
- Upcoming Omni CommercializationCeriBell plans to initiate a limited market release of Omni in Q3 2026 and expects to launch the product in 2027. Management highlighted 8 FDA-cleared algorithms on the platform and 9 FDA clearances achieved during the last 18 months.
- Gross Margin ExpansionQ3 gross margin was 90%, compared with 88% in the prior-year period. Based on current tariff policy and inventory levels, management expects margins to remain in the high 80% range going forward.
- Reduced Expected Interest ExpenseFollowing the transition to a new revolver-first debt structure, CeriBell expects interest expense to decrease materially to less than $1 million annually.
- Strong Liquidity and Cash Breakeven ObjectiveCash, cash equivalents, and marketable securities totaled $117.5 million as of September 30, 2026. Management remains committed to achieving cash flow breakeven with cash on hand and said the balance sheet and gross margin profile provide a high degree of confidence in that objective.
- 2026 Revenue Guidance IncreasedFull-year 2026 revenue guidance was raised to $115 million to $117 million from the prior range of $114 million to $117 million. The new range represents annual growth of 29% to 31% over 2025 and reflects momentum from both new account additions and usage within established accounts.
- Large Remaining Core Market OpportunityManagement stated that CeriBell has less than 4% penetration in its core seizure market, indicating that the company views significant market opportunity as it advances into additional greenfield markets.
CBLL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -0.50- | -0.36 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | -0.51-0.55 | -0.37 | -48.65% (-0.18) | |
| Aug 10, 2026 | 2026 (Q2) | -0.47-0.51 | -0.38 | -34.21% (-0.13) | |
| May 11, 2026 | 2026 (Q1) | -0.39-0.52 | -0.36 | -44.44% (-0.16) | |
| Feb 24, 2026 | 2025 (Q4) | -0.41-0.36 | -0.4 | 10.00% (+0.04) | |
| Nov 04, 2025 | 2025 (Q3) | -0.41-0.37 | -1.85 | 80.00% (+1.48) | |
| Aug 05, 2025 | 2025 (Q2) | -0.40-0.38 | -0.37 | -2.15% (-0.01) | |
| May 08, 2025 | 2025 (Q1) | -0.41-0.36 | ― | ― | |
| Feb 25, 2025 | 2024 (Q4) | -0.32-0.40 | ― | ― | |
| Nov 12, 2024 | 2024 (Q3) | -0.34-1.85 | ― | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
